The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO 2024 | Refining biomarker-based therapies for HER2+ gastric or gastroesophageal junction cancer
Yelena Janjigian, MD, Memorial Sloan Kettering Cancer Center, New York, NY, explores the evolving understanding of tumor complexity and its impact on patient outcomes, with a focus on HER2-positive gastric or gastroesophageal junction cancer in the KEYNOTE-811 study (NCT03615326). Chromosomal instability, and alterations in HER2+ tumors, are linked to survival, which could help predict patient prognosis. Potential strategies like escalating therapies or utilizing trastuzumab deruxtecan (TDXd) for its targeted and bystander effects are also examined. This interview took place at the European Society for Medical Oncology (ESMO) 2024 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
